| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterococcus faecalis | 36 | 2025 | 44 | 13.840 |
Why?
|
| Biofilms | 23 | 2025 | 178 | 5.630 |
Why?
|
| Urinary Tract Infections | 19 | 2023 | 42 | 4.820 |
Why?
|
| Vitamin E | 25 | 2012 | 56 | 4.290 |
Why?
|
| Bacterial Proteins | 19 | 2025 | 580 | 3.690 |
Why?
|
| Gram-Positive Bacterial Infections | 13 | 2025 | 20 | 3.650 |
Why?
|
| Aminoacyltransferases | 7 | 2025 | 7 | 3.480 |
Why?
|
| Fimbriae, Bacterial | 11 | 2025 | 26 | 3.230 |
Why?
|
| Apoptosis | 24 | 2012 | 1541 | 2.790 |
Why?
|
| Anti-Bacterial Agents | 15 | 2025 | 415 | 2.790 |
Why?
|
| Cysteine Endopeptidases | 7 | 2025 | 64 | 2.660 |
Why?
|
| Tocopherols | 25 | 2011 | 61 | 2.570 |
Why?
|
| Wound Infection | 8 | 2025 | 8 | 2.170 |
Why?
|
| Breast Neoplasms | 24 | 2023 | 1679 | 2.150 |
Why?
|
| Staphylococcus aureus | 3 | 2022 | 91 | 1.910 |
Why?
|
| Escherichia coli Infections | 8 | 2022 | 43 | 1.690 |
Why?
|
| Bacterial Adhesion | 7 | 2025 | 40 | 1.570 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 74 | 1.550 |
Why?
|
| Antineoplastic Agents | 13 | 2012 | 979 | 1.510 |
Why?
|
| Fimbriae Proteins | 9 | 2022 | 21 | 1.450 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 6 | 2025 | 62 | 1.320 |
Why?
|
| Gram-Positive Bacteria | 3 | 2016 | 18 | 1.310 |
Why?
|
| Virulence Factors | 8 | 2020 | 119 | 1.270 |
Why?
|
| Host-Pathogen Interactions | 4 | 2024 | 203 | 1.250 |
Why?
|
| Escherichia coli | 6 | 2022 | 461 | 1.220 |
Why?
|
| alpha-Tocopherol | 7 | 2012 | 27 | 1.210 |
Why?
|
| Streptococcus pyogenes | 2 | 2019 | 28 | 1.200 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 5 | 2012 | 10 | 1.190 |
Why?
|
| Urinary Tract | 4 | 2019 | 8 | 1.180 |
Why?
|
| Bacterial Infections | 2 | 2021 | 44 | 1.170 |
Why?
|
| Disease Models, Animal | 11 | 2025 | 1554 | 1.170 |
Why?
|
| Streptococcal Infections | 4 | 2019 | 36 | 1.160 |
Why?
|
| Animals | 48 | 2025 | 16695 | 1.150 |
Why?
|
| Mice | 30 | 2025 | 6490 | 1.150 |
Why?
|
| Neisseria gonorrhoeae | 7 | 2007 | 16 | 1.120 |
Why?
|
| Staphylococcal Infections | 4 | 2025 | 65 | 1.100 |
Why?
|
| Microbial Interactions | 2 | 2016 | 11 | 1.010 |
Why?
|
| Daptomycin | 2 | 2024 | 2 | 1.000 |
Why?
|
| Membrane Proteins | 2 | 2022 | 548 | 0.970 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2023 | 37 | 0.960 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 8 | 2012 | 82 | 0.960 |
Why?
|
| Molecular Chaperones | 2 | 2024 | 68 | 0.920 |
Why?
|
| Catheter-Related Infections | 5 | 2018 | 14 | 0.910 |
Why?
|
| Adhesins, Bacterial | 2 | 2018 | 20 | 0.900 |
Why?
|
| Uropathogenic Escherichia coli | 5 | 2020 | 8 | 0.890 |
Why?
|
| Escherichia coli Proteins | 3 | 2022 | 133 | 0.890 |
Why?
|
| Humans | 66 | 2025 | 42163 | 0.880 |
Why?
|
| Ferric Compounds | 1 | 2025 | 62 | 0.870 |
Why?
|
| Streptococcus agalactiae | 3 | 2014 | 8 | 0.860 |
Why?
|
| Peptide Hydrolases | 1 | 2024 | 44 | 0.850 |
Why?
|
| Virulence | 7 | 2024 | 238 | 0.850 |
Why?
|
| Cell Division | 17 | 2020 | 314 | 0.830 |
Why?
|
| Health Promotion | 3 | 2023 | 691 | 0.800 |
Why?
|
| Electron Transport | 2 | 2025 | 45 | 0.780 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 118 | 0.780 |
Why?
|
| Phosphotransferases | 1 | 2022 | 35 | 0.770 |
Why?
|
| Iron | 3 | 2022 | 247 | 0.770 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2022 | 13 | 0.750 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2022 | 62 | 0.730 |
Why?
|
| Health Education | 3 | 2016 | 358 | 0.720 |
Why?
|
| Tumor Cells, Cultured | 18 | 2010 | 506 | 0.720 |
Why?
|
| Recombination, Genetic | 5 | 2007 | 96 | 0.710 |
Why?
|
| Adenosine Triphosphatases | 3 | 2013 | 83 | 0.710 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2010 | 12 | 0.680 |
Why?
|
| DNA-Binding Proteins | 4 | 2011 | 557 | 0.670 |
Why?
|
| Staphylococcus | 3 | 2022 | 8 | 0.660 |
Why?
|
| Transcription Factor CHOP | 4 | 2012 | 11 | 0.650 |
Why?
|
| Cell Line, Tumor | 14 | 2012 | 2598 | 0.640 |
Why?
|
| Transcription Factors | 3 | 2022 | 722 | 0.640 |
Why?
|
| Female | 38 | 2023 | 24018 | 0.620 |
Why?
|
| Endoplasmic Reticulum | 2 | 2010 | 108 | 0.620 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 428 | 0.610 |
Why?
|
| Immune System | 1 | 2019 | 40 | 0.610 |
Why?
|
| Manganese | 1 | 2020 | 89 | 0.610 |
Why?
|
| Enterococcus | 1 | 2019 | 8 | 0.600 |
Why?
|
| Immune Tolerance | 2 | 2017 | 67 | 0.600 |
Why?
|
| Nuclear Proteins | 3 | 2011 | 330 | 0.600 |
Why?
|
| Streptolysins | 1 | 2018 | 4 | 0.590 |
Why?
|
| Signal Transduction | 12 | 2017 | 2111 | 0.590 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2018 | 11 | 0.590 |
Why?
|
| Antioxidants | 8 | 2012 | 439 | 0.590 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2010 | 30 | 0.580 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 1804 | 0.580 |
Why?
|
| Minority Groups | 1 | 2023 | 663 | 0.570 |
Why?
|
| Lung Neoplasms | 5 | 2008 | 479 | 0.570 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 101 | 0.570 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 4 | 2010 | 9 | 0.560 |
Why?
|
| Blotting, Western | 11 | 2012 | 884 | 0.560 |
Why?
|
| Immune Evasion | 1 | 2017 | 17 | 0.560 |
Why?
|
| Transforming Growth Factor beta | 8 | 2002 | 214 | 0.560 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2011 | 222 | 0.540 |
Why?
|
| MAP Kinase Kinase 4 | 5 | 2011 | 31 | 0.540 |
Why?
|
| Enterococcus faecium | 1 | 2017 | 1 | 0.540 |
Why?
|
| Ornithine | 1 | 2016 | 1 | 0.520 |
Why?
|
| Urinary Catheterization | 1 | 2016 | 4 | 0.520 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 8 | 0.520 |
Why?
|
| Bacteriuria | 1 | 2016 | 2 | 0.500 |
Why?
|
| Membrane Microdomains | 2 | 2017 | 53 | 0.490 |
Why?
|
| Macrophages | 7 | 2024 | 515 | 0.490 |
Why?
|
| Breast Self-Examination | 3 | 2000 | 13 | 0.490 |
Why?
|
| Chromans | 2 | 2012 | 14 | 0.490 |
Why?
|
| Sulfonamides | 2 | 2008 | 88 | 0.480 |
Why?
|
| DNA Helicases | 3 | 2006 | 46 | 0.470 |
Why?
|
| Membrane Transport Proteins | 2 | 2013 | 98 | 0.470 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2007 | 69 | 0.460 |
Why?
|
| Self Care | 1 | 2016 | 173 | 0.440 |
Why?
|
| Urinary Bladder | 6 | 2016 | 30 | 0.440 |
Why?
|
| DNA, Bacterial | 6 | 2017 | 207 | 0.440 |
Why?
|
| Parity | 1 | 2014 | 60 | 0.430 |
Why?
|
| beta-Defensins | 1 | 2013 | 4 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-jun | 4 | 2008 | 24 | 0.420 |
Why?
|
| Mice, Inbred C3H | 6 | 2013 | 80 | 0.410 |
Why?
|
| Vancomycin | 3 | 2025 | 7 | 0.410 |
Why?
|
| DNA Repair | 3 | 2006 | 196 | 0.410 |
Why?
|
| Cell Survival | 6 | 2024 | 934 | 0.400 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 88 | 0.390 |
Why?
|
| gamma-Tocopherol | 1 | 2012 | 19 | 0.390 |
Why?
|
| Antigenic Variation | 3 | 2007 | 8 | 0.390 |
Why?
|
| Ceramides | 1 | 2012 | 43 | 0.380 |
Why?
|
| Docosahexaenoic Acids | 1 | 2012 | 18 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2010 | 152 | 0.380 |
Why?
|
| Gene Expression Regulation, Bacterial | 5 | 2024 | 168 | 0.370 |
Why?
|
| DNA, Neoplasm | 5 | 2004 | 92 | 0.370 |
Why?
|
| Cell Membrane | 3 | 2024 | 400 | 0.370 |
Why?
|
| RNA, Small Interfering | 5 | 2012 | 436 | 0.360 |
Why?
|
| Transformation, Genetic | 2 | 2016 | 21 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 209 | 0.360 |
Why?
|
| Fas Ligand Protein | 2 | 2008 | 17 | 0.360 |
Why?
|
| Tamoxifen | 1 | 2011 | 67 | 0.350 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 43 | 0.350 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 136 | 0.350 |
Why?
|
| Mass Media | 4 | 2013 | 38 | 0.350 |
Why?
|
| 1-Phosphatidylinositol 4-Kinase | 1 | 2010 | 2 | 0.350 |
Why?
|
| Anticarcinogenic Agents | 2 | 2004 | 74 | 0.340 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2010 | 23 | 0.340 |
Why?
|
| Aging | 2 | 2015 | 764 | 0.340 |
Why?
|
| Nanoparticles | 2 | 2025 | 449 | 0.340 |
Why?
|
| Phosphatidylglycerols | 2 | 2023 | 11 | 0.330 |
Why?
|
| Prostatic Neoplasms | 3 | 2008 | 1068 | 0.330 |
Why?
|
| Tocotrienols | 1 | 2010 | 2 | 0.330 |
Why?
|
| Cisplatin | 2 | 2011 | 91 | 0.330 |
Why?
|
| Cholesterol | 1 | 2011 | 230 | 0.320 |
Why?
|
| Gram-Negative Bacteria | 1 | 2010 | 27 | 0.320 |
Why?
|
| Pyrazoles | 2 | 2008 | 93 | 0.320 |
Why?
|
| Caspase 8 | 4 | 2010 | 32 | 0.300 |
Why?
|
| Gastrointestinal Tract | 2 | 2020 | 67 | 0.300 |
Why?
|
| Pamphlets | 2 | 2007 | 27 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 233 | 0.290 |
Why?
|
| Stress, Physiological | 1 | 2010 | 170 | 0.290 |
Why?
|
| Semen Preservation | 2 | 2020 | 18 | 0.290 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2011 | 290 | 0.290 |
Why?
|
| Cryopreservation | 2 | 2020 | 33 | 0.290 |
Why?
|
| Bibliometrics | 2 | 2013 | 15 | 0.290 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 744 | 0.280 |
Why?
|
| Organoselenium Compounds | 1 | 2008 | 9 | 0.280 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2019 | 34 | 0.280 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2008 | 22 | 0.280 |
Why?
|
| Stilbenes | 1 | 2008 | 44 | 0.270 |
Why?
|
| Ultraviolet Rays | 1 | 2008 | 118 | 0.270 |
Why?
|
| Proteome | 2 | 2023 | 150 | 0.270 |
Why?
|
| Health Services Research | 2 | 2006 | 161 | 0.270 |
Why?
|
| Mammography | 2 | 2007 | 211 | 0.270 |
Why?
|
| Polymers | 3 | 2025 | 151 | 0.260 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2007 | 50 | 0.260 |
Why?
|
| Male | 14 | 2024 | 22779 | 0.260 |
Why?
|
| RNA, Messenger | 8 | 2012 | 1265 | 0.260 |
Why?
|
| Thymus Neoplasms | 2 | 1997 | 4 | 0.250 |
Why?
|
| Bacteria | 1 | 2009 | 285 | 0.250 |
Why?
|
| Lactic Acid | 2 | 2022 | 110 | 0.240 |
Why?
|
| Metals | 2 | 2020 | 113 | 0.240 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 175 | 0.240 |
Why?
|
| RNA Interference | 3 | 2012 | 246 | 0.240 |
Why?
|
| Dental Pulp Cavity | 1 | 2025 | 3 | 0.240 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2024 | 232 | 0.240 |
Why?
|
| Kidney | 4 | 2012 | 363 | 0.240 |
Why?
|
| Cyclins | 2 | 2002 | 37 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2012 | 933 | 0.230 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2025 | 10 | 0.230 |
Why?
|
| Liposomes | 4 | 2008 | 130 | 0.230 |
Why?
|
| Mammals | 2 | 2023 | 109 | 0.230 |
Why?
|
| Neutrophils | 3 | 2011 | 141 | 0.230 |
Why?
|
| Acute Disease | 2 | 2015 | 156 | 0.220 |
Why?
|
| Ceftriaxone | 1 | 2024 | 7 | 0.220 |
Why?
|
| Cell Wall | 2 | 2022 | 55 | 0.220 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 534 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2010 | 1112 | 0.210 |
Why?
|
| Aniline Compounds | 1 | 2024 | 27 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 649 | 0.210 |
Why?
|
| Cell Cycle Proteins | 2 | 2020 | 239 | 0.210 |
Why?
|
| Keratinocytes | 1 | 2024 | 67 | 0.210 |
Why?
|
| Carbohydrates | 1 | 2023 | 32 | 0.210 |
Why?
|
| Purines | 1 | 2023 | 40 | 0.210 |
Why?
|
| Phagocytosis | 1 | 2024 | 83 | 0.210 |
Why?
|
| Cross Infection | 2 | 2015 | 47 | 0.210 |
Why?
|
| Mutation | 3 | 2024 | 1169 | 0.210 |
Why?
|
| Pyelonephritis | 2 | 2014 | 3 | 0.210 |
Why?
|
| Up-Regulation | 3 | 2012 | 534 | 0.210 |
Why?
|
| Ovarian Neoplasms | 2 | 2006 | 406 | 0.210 |
Why?
|
| Neisseria meningitidis | 1 | 2003 | 17 | 0.210 |
Why?
|
| Self Efficacy | 3 | 2016 | 211 | 0.210 |
Why?
|
| Wound Healing | 1 | 2024 | 82 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 2 | 2002 | 189 | 0.200 |
Why?
|
| Vancomycin Resistance | 1 | 2023 | 2 | 0.200 |
Why?
|
| Mitoxantrone | 1 | 2023 | 3 | 0.200 |
Why?
|
| Horses | 2 | 2020 | 28 | 0.200 |
Why?
|
| Neoplasm Proteins | 3 | 2012 | 228 | 0.200 |
Why?
|
| Cations | 1 | 2023 | 49 | 0.200 |
Why?
|
| Protein Transport | 2 | 2016 | 295 | 0.200 |
Why?
|
| DNA Replication | 1 | 2003 | 153 | 0.190 |
Why?
|
| Microbial Viability | 2 | 2016 | 42 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2023 | 350 | 0.190 |
Why?
|
| Cell Cycle | 2 | 2002 | 348 | 0.190 |
Why?
|
| N-Methylaspartate | 1 | 2022 | 58 | 0.190 |
Why?
|
| Cell Line | 4 | 2025 | 1416 | 0.190 |
Why?
|
| Phospholipids | 1 | 2023 | 69 | 0.190 |
Why?
|
| Aged | 4 | 2023 | 7982 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 471 | 0.190 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 6 | 0.190 |
Why?
|
| Endosomes | 1 | 2022 | 34 | 0.190 |
Why?
|
| Doxycycline | 1 | 2002 | 32 | 0.180 |
Why?
|
| Fatty Acids | 1 | 2023 | 134 | 0.180 |
Why?
|
| Mutagens | 1 | 2022 | 76 | 0.180 |
Why?
|
| Heme | 1 | 2022 | 72 | 0.180 |
Why?
|
| Texas | 1 | 2023 | 428 | 0.180 |
Why?
|
| Cytokines | 3 | 2011 | 661 | 0.180 |
Why?
|
| Lysosomes | 1 | 2022 | 88 | 0.180 |
Why?
|
| Drug Synergism | 3 | 2010 | 189 | 0.180 |
Why?
|
| Carbon | 1 | 2022 | 127 | 0.180 |
Why?
|
| Phosphorylation | 3 | 2011 | 973 | 0.170 |
Why?
|
| Lymphocyte Activation | 3 | 2011 | 244 | 0.170 |
Why?
|
| Drug Carriers | 2 | 2018 | 169 | 0.170 |
Why?
|
| Growth Inhibitors | 1 | 2001 | 29 | 0.170 |
Why?
|
| Genes, Essential | 1 | 2020 | 6 | 0.170 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2008 | 147 | 0.170 |
Why?
|
| Biological Transport | 2 | 2020 | 201 | 0.170 |
Why?
|
| Carrier Proteins | 1 | 2023 | 318 | 0.170 |
Why?
|
| Molecular Sequence Data | 5 | 2007 | 1559 | 0.170 |
Why?
|
| DNA Primers | 2 | 2013 | 295 | 0.170 |
Why?
|
| Models, Theoretical | 2 | 2018 | 230 | 0.170 |
Why?
|
| Journalism, Medical | 2 | 2013 | 5 | 0.170 |
Why?
|
| Time Factors | 4 | 2010 | 1848 | 0.170 |
Why?
|
| Mitochondria | 3 | 2010 | 516 | 0.170 |
Why?
|
| Intracellular Space | 1 | 2020 | 37 | 0.160 |
Why?
|
| Cell Differentiation | 2 | 2002 | 633 | 0.160 |
Why?
|
| Quorum Sensing | 1 | 2020 | 14 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2020 | 61 | 0.160 |
Why?
|
| Gene Expression | 4 | 2020 | 692 | 0.160 |
Why?
|
| Reactive Oxygen Species | 3 | 2024 | 518 | 0.160 |
Why?
|
| Base Sequence | 4 | 2008 | 997 | 0.160 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 233 | 0.160 |
Why?
|
| NF-kappa B | 2 | 2024 | 355 | 0.160 |
Why?
|
| Peptides | 1 | 2022 | 357 | 0.150 |
Why?
|
| Blood | 1 | 2019 | 37 | 0.150 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 32 | 0.150 |
Why?
|
| Fenretinide | 1 | 1999 | 9 | 0.150 |
Why?
|
| Endocarditis, Bacterial | 1 | 2018 | 6 | 0.150 |
Why?
|
| Bacteriological Techniques | 1 | 2018 | 15 | 0.150 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2018 | 24 | 0.150 |
Why?
|
| Pheromones | 1 | 2018 | 18 | 0.150 |
Why?
|
| Risk Factors | 3 | 2015 | 3942 | 0.150 |
Why?
|
| Homeostasis | 1 | 2020 | 193 | 0.150 |
Why?
|
| Tumor Burden | 2 | 2010 | 84 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 129 | 0.150 |
Why?
|
| Caspases | 2 | 2010 | 148 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2010 | 1420 | 0.140 |
Why?
|
| Polyesters | 1 | 2018 | 26 | 0.140 |
Why?
|
| Inflammation | 2 | 2016 | 729 | 0.140 |
Why?
|
| Middle Aged | 5 | 2023 | 11819 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2020 | 237 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2019 | 168 | 0.140 |
Why?
|
| Lymphatic Metastasis | 2 | 2008 | 81 | 0.140 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2018 | 64 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 502 | 0.140 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 72 | 0.140 |
Why?
|
| Cell Nucleus | 2 | 2011 | 383 | 0.140 |
Why?
|
| Heart | 1 | 2019 | 181 | 0.140 |
Why?
|
| Adaptation, Psychological | 1 | 2000 | 410 | 0.140 |
Why?
|
| Nitriles | 2 | 2024 | 78 | 0.140 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2008 | 34 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2011 | 297 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 686 | 0.130 |
Why?
|
| Prospective Studies | 1 | 2021 | 1574 | 0.130 |
Why?
|
| Enterobactin | 1 | 2016 | 1 | 0.130 |
Why?
|
| Fear | 1 | 2000 | 271 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 2018 | 181 | 0.130 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2008 | 95 | 0.130 |
Why?
|
| Lymphoma | 1 | 1997 | 38 | 0.130 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2010 | 78 | 0.130 |
Why?
|
| Lysine | 1 | 2017 | 120 | 0.130 |
Why?
|
| Transformation, Bacterial | 3 | 2006 | 12 | 0.130 |
Why?
|
| Health Behavior | 1 | 2000 | 568 | 0.130 |
Why?
|
| Protein Sorting Signals | 1 | 2016 | 26 | 0.120 |
Why?
|
| Bone Marrow | 2 | 1995 | 35 | 0.120 |
Why?
|
| Centrifugation | 1 | 2016 | 6 | 0.120 |
Why?
|
| Filtration | 1 | 2016 | 17 | 0.120 |
Why?
|
| Television | 1 | 2016 | 28 | 0.120 |
Why?
|
| Thymoma | 1 | 1996 | 2 | 0.120 |
Why?
|
| Models, Biological | 2 | 2010 | 711 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 105 | 0.120 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2016 | 58 | 0.120 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1995 | 19 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2015 | 24 | 0.120 |
Why?
|
| Disinfection | 1 | 2015 | 10 | 0.120 |
Why?
|
| Chromatography, Liquid | 2 | 2017 | 173 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 273 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 457 | 0.120 |
Why?
|
| Water Purification | 1 | 2015 | 33 | 0.120 |
Why?
|
| Skin | 2 | 2025 | 185 | 0.120 |
Why?
|
| Mice, Nude | 2 | 2008 | 403 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 1995 | 1 | 0.120 |
Why?
|
| Receptors, Fibronectin | 1 | 1995 | 3 | 0.120 |
Why?
|
| Chitosan | 1 | 2015 | 52 | 0.120 |
Why?
|
| Water Microbiology | 1 | 2015 | 82 | 0.110 |
Why?
|
| Allergy and Immunology | 1 | 1995 | 13 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2007 | 256 | 0.110 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1995 | 36 | 0.110 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2017 | 230 | 0.110 |
Why?
|
| Cultural Diversity | 2 | 2007 | 187 | 0.110 |
Why?
|
| Fibronectins | 1 | 1995 | 69 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2016 | 358 | 0.110 |
Why?
|
| Graphite | 1 | 2015 | 61 | 0.110 |
Why?
|
| Cystitis | 1 | 2014 | 7 | 0.110 |
Why?
|
| Adult | 3 | 2023 | 13458 | 0.110 |
Why?
|
| Spermatozoa | 1 | 2016 | 208 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2021 | 583 | 0.110 |
Why?
|
| Amino Acid Sequence | 3 | 2005 | 1188 | 0.110 |
Why?
|
| Meningococcal Vaccines | 1 | 2013 | 6 | 0.110 |
Why?
|
| Hydro-Lyases | 1 | 2013 | 11 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 64 | 0.100 |
Why?
|
| Kinetics | 2 | 2008 | 698 | 0.100 |
Why?
|
| Nanostructures | 1 | 2015 | 158 | 0.100 |
Why?
|
| Serine | 1 | 2013 | 81 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 196 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2006 | 462 | 0.100 |
Why?
|
| Mannosides | 1 | 2012 | 3 | 0.100 |
Why?
|
| Caspases, Initiator | 1 | 2012 | 3 | 0.100 |
Why?
|
| Molecular Weight | 4 | 2012 | 168 | 0.100 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2012 | 22 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2002 | 56 | 0.090 |
Why?
|
| Internet | 1 | 2013 | 234 | 0.090 |
Why?
|
| Spleen | 2 | 1984 | 199 | 0.090 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2002 | 40 | 0.090 |
Why?
|
| beta-Cyclodextrins | 1 | 2011 | 35 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2010 | 94 | 0.090 |
Why?
|
| Sialic Acids | 1 | 2011 | 3 | 0.090 |
Why?
|
| Culture Media, Conditioned | 3 | 1996 | 49 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2002 | 103 | 0.090 |
Why?
|
| Bacterial Capsules | 1 | 2011 | 8 | 0.090 |
Why?
|
| Age Factors | 2 | 2014 | 1139 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2002 | 100 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2011 | 8 | 0.090 |
Why?
|
| Anthracenes | 1 | 2010 | 15 | 0.090 |
Why?
|
| Butadienes | 1 | 2010 | 29 | 0.090 |
Why?
|
| Androstadienes | 1 | 2010 | 19 | 0.090 |
Why?
|
| Caspase 9 | 1 | 2010 | 30 | 0.090 |
Why?
|
| Papillomavirus Vaccines | 1 | 2013 | 168 | 0.090 |
Why?
|
| Cytochromes c | 1 | 2010 | 48 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2014 | 541 | 0.080 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2004 | 25 | 0.080 |
Why?
|
| Cytosol | 1 | 2010 | 98 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 90 | 0.080 |
Why?
|
| Sirolimus | 1 | 2010 | 70 | 0.080 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 74 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2011 | 95 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2010 | 47 | 0.080 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 67 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 508 | 0.080 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1990 | 27 | 0.080 |
Why?
|
| Microscopy | 1 | 2010 | 33 | 0.080 |
Why?
|
| N-Acetylmuramoyl-L-alanine Amidase | 1 | 2009 | 5 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 177 | 0.080 |
Why?
|
| Blotting, Northern | 2 | 2002 | 149 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2011 | 149 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 2 | 2008 | 207 | 0.080 |
Why?
|
| Lymphocytes | 2 | 2007 | 124 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 2803 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2010 | 205 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2009 | 181 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 160 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 18 | 0.070 |
Why?
|
| Neoplasms | 2 | 2001 | 1341 | 0.070 |
Why?
|
| Vitamins | 2 | 2008 | 81 | 0.070 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2008 | 3 | 0.070 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2008 | 28 | 0.070 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 2 | 0.070 |
Why?
|
| Mice, Hairless | 1 | 2008 | 7 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 254 | 0.070 |
Why?
|
| Co-Repressor Proteins | 1 | 2008 | 18 | 0.070 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2008 | 29 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 2005 | 273 | 0.070 |
Why?
|
| Morpholines | 1 | 2008 | 73 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 34 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2008 | 37 | 0.070 |
Why?
|
| Chromones | 1 | 2008 | 53 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2008 | 92 | 0.070 |
Why?
|
| Acetates | 1 | 2008 | 29 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 75 | 0.070 |
Why?
|
| Phosphatidylcholines | 1 | 2007 | 35 | 0.070 |
Why?
|
| Antigens, Bacterial | 3 | 2006 | 144 | 0.070 |
Why?
|
| Polyglycolic Acid | 1 | 2007 | 48 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2007 | 73 | 0.070 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2007 | 36 | 0.070 |
Why?
|
| Mutagenesis, Insertional | 1 | 2007 | 35 | 0.070 |
Why?
|
| Carcinoma | 1 | 2008 | 106 | 0.070 |
Why?
|
| DNA Transposable Elements | 1 | 2007 | 50 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2007 | 92 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 339 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2008 | 126 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 150 | 0.060 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 20 | 0.060 |
Why?
|
| DNA, Cruciform | 1 | 2006 | 3 | 0.060 |
Why?
|
| Particle Size | 1 | 2007 | 267 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 206 | 0.060 |
Why?
|
| Social Identification | 1 | 2007 | 63 | 0.060 |
Why?
|
| Social Perception | 1 | 2007 | 71 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 98 | 0.060 |
Why?
|
| Social Conditions | 1 | 2006 | 13 | 0.060 |
Why?
|
| Benzene Derivatives | 1 | 2005 | 4 | 0.060 |
Why?
|
| Body Weight | 1 | 2007 | 428 | 0.060 |
Why?
|
| Cell Transformation, Viral | 2 | 1999 | 22 | 0.060 |
Why?
|
| Oxidants | 1 | 2005 | 43 | 0.060 |
Why?
|
| Free Radicals | 1 | 2005 | 72 | 0.060 |
Why?
|
| Forecasting | 1 | 2006 | 136 | 0.060 |
Why?
|
| Gentamicins | 1 | 2025 | 10 | 0.060 |
Why?
|
| Phytohemagglutinins | 2 | 1984 | 15 | 0.060 |
Why?
|
| Concanavalin A | 2 | 1984 | 10 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2004 | 41 | 0.060 |
Why?
|
| Nitrophenols | 1 | 2004 | 5 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2006 | 452 | 0.060 |
Why?
|
| Esterases | 1 | 2004 | 8 | 0.060 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 1984 | 3 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2004 | 38 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2004 | 98 | 0.050 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 193 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 683 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2004 | 151 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 287 | 0.050 |
Why?
|
| Communication | 1 | 2006 | 207 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2007 | 359 | 0.050 |
Why?
|
| Quinolines | 1 | 2024 | 76 | 0.050 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2023 | 30 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2008 | 1586 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2002 | 1066 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2004 | 94 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 62 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2021 | 959 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2023 | 59 | 0.050 |
Why?
|
| Lipids | 1 | 2025 | 256 | 0.050 |
Why?
|
| Aerosols | 1 | 2003 | 53 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 138 | 0.050 |
Why?
|
| Retroviridae | 2 | 1995 | 25 | 0.050 |
Why?
|
| DNA Damage | 1 | 2005 | 358 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2024 | 278 | 0.050 |
Why?
|
| Genes, jun | 1 | 2002 | 7 | 0.050 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2002 | 14 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 15 | 0.050 |
Why?
|
| Keratins | 1 | 2002 | 25 | 0.050 |
Why?
|
| Gene Deletion | 3 | 2012 | 168 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 40 | 0.050 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2001 | 3 | 0.050 |
Why?
|
| Luciferases | 1 | 2002 | 70 | 0.050 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2001 | 27 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2001 | 52 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2024 | 426 | 0.040 |
Why?
|
| Transfection | 1 | 2002 | 526 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 173 | 0.040 |
Why?
|
| Cryoprotective Agents | 1 | 2020 | 6 | 0.040 |
Why?
|
| Freezing | 1 | 2020 | 17 | 0.040 |
Why?
|
| United States | 2 | 2013 | 5072 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 522 | 0.040 |
Why?
|
| Carbohydrate Sequence | 1 | 2020 | 20 | 0.040 |
Why?
|
| Mannans | 1 | 2020 | 4 | 0.040 |
Why?
|
| Acetylglucosamine | 1 | 2020 | 8 | 0.040 |
Why?
|
| Haemophilus influenzae | 1 | 2020 | 6 | 0.040 |
Why?
|
| Semen | 1 | 2020 | 55 | 0.040 |
Why?
|
| Persuasive Communication | 1 | 2000 | 9 | 0.040 |
Why?
|
| Counseling | 1 | 2021 | 134 | 0.040 |
Why?
|
| Women's Health | 1 | 2000 | 158 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2020 | 70 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 255 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 1999 | 36 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2000 | 236 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2000 | 411 | 0.040 |
Why?
|
| alpha-2-Antiplasmin | 1 | 1999 | 1 | 0.040 |
Why?
|
| Mannosephosphates | 1 | 1999 | 1 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 293 | 0.040 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1999 | 20 | 0.040 |
Why?
|
| Plasmodium falciparum | 1 | 2000 | 146 | 0.040 |
Why?
|
| Protein Kinases | 1 | 1999 | 100 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 183 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2018 | 108 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 1999 | 268 | 0.030 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2017 | 22 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2021 | 362 | 0.030 |
Why?
|
| Diglycerides | 1 | 2017 | 9 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2017 | 12 | 0.030 |
Why?
|
| Adolescent | 3 | 2021 | 5950 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2023 | 990 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2003 | 599 | 0.030 |
Why?
|
| Biotransformation | 1 | 2017 | 68 | 0.030 |
Why?
|
| Thymidine | 1 | 1997 | 15 | 0.030 |
Why?
|
| Drug Design | 1 | 2018 | 183 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 1997 | 31 | 0.030 |
Why?
|
| Probiotics | 1 | 2017 | 37 | 0.030 |
Why?
|
| Triglycerides | 1 | 2017 | 146 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 90 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1997 | 62 | 0.030 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 68 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 190 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1076 | 0.030 |
Why?
|
| Proteins | 1 | 1999 | 383 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1997 | 82 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 740 | 0.030 |
Why?
|
| Sperm Motility | 1 | 2016 | 45 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1996 | 42 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 140 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 454 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 2015 | 55 | 0.030 |
Why?
|
| Electrodes | 1 | 2015 | 57 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1996 | 90 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 143 | 0.030 |
Why?
|
| Cations, Divalent | 1 | 1995 | 25 | 0.030 |
Why?
|
| Edetic Acid | 1 | 1995 | 23 | 0.030 |
Why?
|
| Trypsin | 1 | 1995 | 40 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1995 | 96 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1995 | 58 | 0.030 |
Why?
|
| Oxides | 1 | 2015 | 97 | 0.030 |
Why?
|
| Antibodies | 1 | 1995 | 140 | 0.030 |
Why?
|
| Pediococcus | 1 | 1973 | 1 | 0.030 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 1973 | 3 | 0.030 |
Why?
|
| Search Engine | 1 | 2013 | 7 | 0.030 |
Why?
|
| Streptococcus | 1 | 1973 | 18 | 0.030 |
Why?
|
| Longevity | 1 | 2016 | 171 | 0.030 |
Why?
|
| Pyruvic Acid | 1 | 2013 | 21 | 0.030 |
Why?
|
| Birds | 1 | 1995 | 93 | 0.030 |
Why?
|
| Lactobacillus | 1 | 1973 | 22 | 0.030 |
Why?
|
| Ammonia | 1 | 2013 | 22 | 0.030 |
Why?
|
| Models, Genetic | 2 | 2006 | 181 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 311 | 0.020 |
Why?
|
| Adhesins, Escherichia coli | 1 | 2012 | 3 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 167 | 0.020 |
Why?
|
| DNA | 1 | 1996 | 594 | 0.020 |
Why?
|
| Cell Membrane Permeability | 2 | 1984 | 57 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2012 | 94 | 0.020 |
Why?
|
| Receptors, Transferrin | 1 | 1992 | 15 | 0.020 |
Why?
|
| G2 Phase | 1 | 1992 | 29 | 0.020 |
Why?
|
| Calcitriol | 1 | 1992 | 32 | 0.020 |
Why?
|
| Tretinoin | 1 | 1992 | 50 | 0.020 |
Why?
|
| Chickens | 2 | 1984 | 148 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1992 | 122 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 198 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 140 | 0.020 |
Why?
|
| Monocytes | 1 | 1992 | 275 | 0.020 |
Why?
|
| Deoxyribonuclease I | 1 | 2009 | 28 | 0.020 |
Why?
|
| Klebsiella pneumoniae | 1 | 2008 | 26 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 74 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2008 | 38 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 95 | 0.020 |
Why?
|
| Nutritional Requirements | 1 | 1987 | 33 | 0.020 |
Why?
|
| Diet Surveys | 1 | 1987 | 97 | 0.020 |
Why?
|
| Rec A Recombinases | 1 | 2006 | 2 | 0.020 |
Why?
|
| Endodeoxyribonucleases | 1 | 2006 | 29 | 0.020 |
Why?
|
| Gonorrhea | 1 | 2006 | 24 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1999 | 1617 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 1987 | 263 | 0.010 |
Why?
|
| Isoantigens | 1 | 1984 | 5 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1984 | 25 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 1984 | 4 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1984 | 25 | 0.010 |
Why?
|
| Isopropyl Thiogalactoside | 1 | 2003 | 1 | 0.010 |
Why?
|
| Cell Separation | 1 | 1984 | 94 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2003 | 35 | 0.010 |
Why?
|
| Bursa of Fabricius | 1 | 1980 | 2 | 0.010 |
Why?
|
| Embryo, Nonmammalian | 1 | 1980 | 59 | 0.010 |
Why?
|
| Methotrexate | 1 | 2000 | 22 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1980 | 74 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 148 | 0.010 |
Why?
|
| Callithrix | 1 | 1999 | 12 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2000 | 97 | 0.010 |
Why?
|
| Sepharose | 1 | 1999 | 17 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1980 | 350 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 1999 | 65 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 247 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2000 | 182 | 0.010 |
Why?
|
| Electrophoresis, Disc | 1 | 1973 | 1 | 0.010 |
Why?
|
| Complement Fixation Tests | 1 | 1973 | 2 | 0.010 |
Why?
|
| Immunoelectrophoresis | 1 | 1973 | 3 | 0.010 |
Why?
|
| Immunodiffusion | 1 | 1973 | 4 | 0.010 |
Why?
|
| Methods | 1 | 1973 | 14 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1973 | 19 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1973 | 15 | 0.010 |
Why?
|
| Species Specificity | 1 | 1973 | 279 | 0.010 |
Why?
|
| Nutritive Value | 1 | 1987 | 37 | 0.000 |
Why?
|
| Restaurants | 1 | 1987 | 39 | 0.000 |
Why?
|
| Minerals | 1 | 1987 | 52 | 0.000 |
Why?
|
| Energy Intake | 1 | 1987 | 162 | 0.000 |
Why?
|
| Sex Factors | 1 | 1987 | 1008 | 0.000 |
Why?
|